Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWJNJ-53718678 is an inhibitor of respiratory syncytial virus (RSV) fusion.1 JNJ-53718678 binds to and stabilizes the RSV fusion protein in its prefusion conformation.2 It reduces RSV replication in RSV-infected HeLa cells (IC50 = 0.5 nM) with a 50% cytotoxic concentration (CC50) of greater than 50 µM.1 JNJ-53718678 (4-100 mg/kg), administered prior to infection, reduces RSV viral titers in lavaged-lung tissue and viral RNA production in the lungs in a semi-permissive cotton rat model of RSV.2 JNJ-53718678 also reduces RSV viral titers in bronchoalveolar lavage fluid (BALF) in a fully replicative neonatal lamb model of RSV when administered at doses of 5 and 25 mg/kg per day.
WARNING This product is not for human or veterinary use.
1. Discovery of 3-
2. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat. Commun. 8(1), 167 (2017).